I haven’t followed this company closely in a while, but I may take a look. The operating-margin and RoE numbers are respectable. SRDX has new management and is a very different company from the days when it relied on JNJ stent royalties for much of its revenue (#msg-91652915).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”